Gastrointestinal stromal tumor (GIST)

Lesly A. Dossett, Nipun Merchant

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the GI tract and account for 1–3 % of all GI malignancies. GISTs arise from the interstitial cells of Cajal, an intestinal pacemaker cell located in and around the myenteric plexus. They typically arise in the stomach (65–70 %) or small intestine (25–45 %). An important immunohistochemical marker is KIT, a membrane receptor with tyrosine kinase activity that is present in most GISTs (80–95 %). Some GISTs (5–7 %) have a mutation in platelet-derived growth factor receptor alpha (PDGFRA) instead. Several factors including tumor site, size greater than 5 cm, and greater than 5 mitoses per 50 high-power field predict aggressive behavior and recurrence. The treatment for localized GISTs is resection. Systemic chemotherapy and radiation are ineffective. The tyrosine kinase inhibitor imatinib improves progression-free survival in patients with metastatic disease, and its use in the adjuvant and neoadjuvant settings is increasingly common. Many patients ultimately develop imatinib resistance, and for these patients, dose escalation or the use of another tyrosine kinase inhibitor is recommended.

Original languageEnglish (US)
Title of host publicationSurgical Oncology a Practical and Comprehensive Approach
PublisherSpringer New York
Pages627-638
Number of pages12
ISBN (Print)9781493914234, 9781493914227
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Protein-Tyrosine Kinases
Interstitial Cells of Cajal
Platelet-Derived Growth Factor alpha Receptor
Myenteric Plexus
Receptor Protein-Tyrosine Kinases
Mitosis
Sarcoma
Disease-Free Survival
Small Intestine
Gastrointestinal Tract
Neoplasms
Stomach
Radiation
Recurrence
Drug Therapy
Mutation
Membranes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dossett, L. A., & Merchant, N. (2015). Gastrointestinal stromal tumor (GIST). In Surgical Oncology a Practical and Comprehensive Approach (pp. 627-638). Springer New York. https://doi.org/10.1007/978-1-4939-1423-4_28

Gastrointestinal stromal tumor (GIST). / Dossett, Lesly A.; Merchant, Nipun.

Surgical Oncology a Practical and Comprehensive Approach. Springer New York, 2015. p. 627-638.

Research output: Chapter in Book/Report/Conference proceedingChapter

Dossett, LA & Merchant, N 2015, Gastrointestinal stromal tumor (GIST). in Surgical Oncology a Practical and Comprehensive Approach. Springer New York, pp. 627-638. https://doi.org/10.1007/978-1-4939-1423-4_28
Dossett LA, Merchant N. Gastrointestinal stromal tumor (GIST). In Surgical Oncology a Practical and Comprehensive Approach. Springer New York. 2015. p. 627-638 https://doi.org/10.1007/978-1-4939-1423-4_28
Dossett, Lesly A. ; Merchant, Nipun. / Gastrointestinal stromal tumor (GIST). Surgical Oncology a Practical and Comprehensive Approach. Springer New York, 2015. pp. 627-638
@inbook{4a362b3ed210407ebe40f441456077dd,
title = "Gastrointestinal stromal tumor (GIST)",
abstract = "Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the GI tract and account for 1–3 {\%} of all GI malignancies. GISTs arise from the interstitial cells of Cajal, an intestinal pacemaker cell located in and around the myenteric plexus. They typically arise in the stomach (65–70 {\%}) or small intestine (25–45 {\%}). An important immunohistochemical marker is KIT, a membrane receptor with tyrosine kinase activity that is present in most GISTs (80–95 {\%}). Some GISTs (5–7 {\%}) have a mutation in platelet-derived growth factor receptor alpha (PDGFRA) instead. Several factors including tumor site, size greater than 5 cm, and greater than 5 mitoses per 50 high-power field predict aggressive behavior and recurrence. The treatment for localized GISTs is resection. Systemic chemotherapy and radiation are ineffective. The tyrosine kinase inhibitor imatinib improves progression-free survival in patients with metastatic disease, and its use in the adjuvant and neoadjuvant settings is increasingly common. Many patients ultimately develop imatinib resistance, and for these patients, dose escalation or the use of another tyrosine kinase inhibitor is recommended.",
author = "Dossett, {Lesly A.} and Nipun Merchant",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-1423-4_28",
language = "English (US)",
isbn = "9781493914234",
pages = "627--638",
booktitle = "Surgical Oncology a Practical and Comprehensive Approach",
publisher = "Springer New York",

}

TY - CHAP

T1 - Gastrointestinal stromal tumor (GIST)

AU - Dossett, Lesly A.

AU - Merchant, Nipun

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the GI tract and account for 1–3 % of all GI malignancies. GISTs arise from the interstitial cells of Cajal, an intestinal pacemaker cell located in and around the myenteric plexus. They typically arise in the stomach (65–70 %) or small intestine (25–45 %). An important immunohistochemical marker is KIT, a membrane receptor with tyrosine kinase activity that is present in most GISTs (80–95 %). Some GISTs (5–7 %) have a mutation in platelet-derived growth factor receptor alpha (PDGFRA) instead. Several factors including tumor site, size greater than 5 cm, and greater than 5 mitoses per 50 high-power field predict aggressive behavior and recurrence. The treatment for localized GISTs is resection. Systemic chemotherapy and radiation are ineffective. The tyrosine kinase inhibitor imatinib improves progression-free survival in patients with metastatic disease, and its use in the adjuvant and neoadjuvant settings is increasingly common. Many patients ultimately develop imatinib resistance, and for these patients, dose escalation or the use of another tyrosine kinase inhibitor is recommended.

AB - Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the GI tract and account for 1–3 % of all GI malignancies. GISTs arise from the interstitial cells of Cajal, an intestinal pacemaker cell located in and around the myenteric plexus. They typically arise in the stomach (65–70 %) or small intestine (25–45 %). An important immunohistochemical marker is KIT, a membrane receptor with tyrosine kinase activity that is present in most GISTs (80–95 %). Some GISTs (5–7 %) have a mutation in platelet-derived growth factor receptor alpha (PDGFRA) instead. Several factors including tumor site, size greater than 5 cm, and greater than 5 mitoses per 50 high-power field predict aggressive behavior and recurrence. The treatment for localized GISTs is resection. Systemic chemotherapy and radiation are ineffective. The tyrosine kinase inhibitor imatinib improves progression-free survival in patients with metastatic disease, and its use in the adjuvant and neoadjuvant settings is increasingly common. Many patients ultimately develop imatinib resistance, and for these patients, dose escalation or the use of another tyrosine kinase inhibitor is recommended.

UR - http://www.scopus.com/inward/record.url?scp=84944063838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944063838&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1423-4_28

DO - 10.1007/978-1-4939-1423-4_28

M3 - Chapter

SN - 9781493914234

SN - 9781493914227

SP - 627

EP - 638

BT - Surgical Oncology a Practical and Comprehensive Approach

PB - Springer New York

ER -